Loading stock data…
Loading stock data…
US$2.31
Get one email when PCSA crosses your level. Checked every 15 minutes during market hours.
▲ +0.07 (3.13%)up today
USD · data via Finnhub · delayed/cached up to 1–5 min
Get an AI-written, balanced deep-dive — performance, valuation, technicals, and the bull vs. bear case. Sign in to get started.
RSI (14-day)
54.3
NeutralAbove 70 can signal overbought; below 30, oversold.
MACD
-0.01
Bullish momentumMACD above its signal line (-0.08).
50-day average
2.35
Price belowShort-term trend reference.
200-day average
4.02
Price belowLong-term trend reference.
Daily values · indicators are descriptive, not trading advice
Healthcare · Biotechnology
Processa Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing Next Generation Cancer therapies. It modifies existing FDA-approved chemotherapy drugs to enhance safety and efficacy by altering their metabolism and distribution while preserving the mechanisms that target cancer cells. The company's pipeline features NGC-Cap, a next-generation capecitabine advancing in Phase 2 trials for metastatic breast cancer and gastrointestinal cancers, providing greater exp…
www.processapharmaceuticals.com2 strong buy · 4 buy · 1 hold · 0 sell · 0 strong sell (7 analysts, 2026-07-01)
2 strong buy · 4 buy · 1 hold · 0 sell · 0 strong sell (7 analysts, 2026-06-01)
2 strong buy · 4 buy · 1 hold · 0 sell · 0 strong sell (7 analysts, 2026-05-01)
2 strong buy · 4 buy · 1 hold · 0 sell · 0 strong sell (7 analysts, 2026-04-01)
| Quarter | Estimate | Actual | Result |
|---|---|---|---|
| 2026-05-20 | 2.91 | 3.09 | ✓ Beat |
| 2026-02-12 | 1.03 | 1.07 | ✓ Beat |
| 2025-11-06 | -2 | -1.75 | ✓ Beat |
| 2025-08-07 | -5.75 | -6.25 | ✗ Miss |
| 2025-05-08 | -19.25 | -7.5 | ✓ Beat |
| 2025-03-20 | -23 | -18.5 | ✓ Beat |
| 2024-10-30 | -25 | -25.75 | ✗ Miss |
| 2024-08-13 | -24.5 | -25.25 | ✗ Miss |
Companies in the same industry, via Finnhub